Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma
John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.
John H. Sampson, MD, PhD, MBA, MHSc, chief, Division of Neurosurgery, Duke University Medical Center, discusses results from cohort 1 of the CHECKMATE-143 trial. Sampson reported these findings at the 2015 Annual Meeting of the Society for Neuro-Oncology.
In this cohort, patients with recurrent glioblastoma were randomized to receive nivolumab in combination with ipilimumab or nivolumab alone. Nivolumab monotherapy demonstrated a superior safety profile.
Sampson added that patients treated with nivolumab monotherapy had a median overall survival of 10.5 months and 40% were alive after one year. This is encouraging, he says, because the median overall survival with bevacizumab (the current standard of care) is between seven and 10 months and the one-year survival rate is 26%.
<<<
